Understanding ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is the #1 cause of cancer-related death worldwide. 1

-2.5 million cases diagnosed globally 2

Despite advancements in treatment, outcomes for lung cancer remain poor. 1

Types of Lung Cancer

The two main types of lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). 3 A subtype of NSCLC is anaplastic lymphoma kinase (ALK)-positive NSCLC. 4

All lung cancer cases 6

NSCLC 80%–85%

SCLC 15%

3%–5% of NSCLC cases are ALK+ NSCLC. 6

~72,000 new cases of ALK+ NSCLC are diagnosed annually worldwide 6

25%–40% of those diagnosed may develop brain metastases within the first two years 7

Half of cases of ALK+ NSCLC are diagnosed before 50 years-old 8

Testing and Treatment Options for ALK+ NSCLC

Biomarker testing is an important first step in the diagnosis of ALK-positive NSCLC. 9

Most people diagnosed will receive an ALK tyrosine kinase inhibitor (TKI) targeted therapy as first treatment. 10

ALK TKIs are a standard of care. 11

Treatment resistance may develop, but innovation and research in this field are helping to address and delay disease progression. 12

Other treatment options for ALK+ NSCLC 13

Surgery

Radiation Therapy

Chemotherapy

1. American Cancer Society, Cancer Facts & Figures 2021
2. GLOBOCAN 2018 v1.2, Cancer Incidence and Mortality rates by age-standardized rates